Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer's Disease?

Int J Mol Sci. 2023 Feb 6;24(4):3205. doi: 10.3390/ijms24043205.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that accounts for more than half of all dementia cases in the elderly. Interestingly, the clinical manifestations of AD disproportionately affect women, comprising two thirds of all AD cases. Although the underlying mechanisms for these sex differences are not fully elucidated, evidence suggests a link between menopause and a higher risk of developing AD, highlighting the critical role of decreased estrogen levels in AD pathogenesis. The focus of this review is to evaluate clinical and observational studies in women, which have investigated the impact of estrogens on cognition or attempted to answer the prevailing question regarding the use of hormone replacement therapy (HRT) as a preventive or therapeutic option for AD. The articles were retrieved through a systematic review of the databases: OVID, SCOPUS, and PubMed (keywords "memory", "dementia," "cognition," "Alzheimer's disease", "estrogen", "estradiol", "hormone therapy" and "hormone replacement therapy" and by searching reference sections from identified studies and review articles). This review presents the relevant literature available on the topic and discusses the mechanisms, effects, and hypotheses that contribute to the conflicting findings of HRT in the prevention and treatment of age-related cognitive deficits and AD. The literature suggests that estrogens have a clear role in modulating dementia risk, with reliable evidence showing that HRT can have both a beneficial and a deleterious effect. Importantly, recommendation for the use of HRT should consider the age of initiation and baseline characteristics, such as genotype and cardiovascular health, as well as the dosage, formulation, and duration of treatment until the risk factors that modulate the effects of HRT can be more thoroughly investigated or progress in the development of alternative treatments can be made.

Keywords: Alzheimer’s disease; cognition; dementia; estradiol; estrogen; hormone replacement therapy; memory.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Aged
  • Alzheimer Disease* / drug therapy
  • Estradiol / therapeutic use
  • Estrogen Replacement Therapy / adverse effects
  • Estrogens / adverse effects
  • Female
  • Hormone Replacement Therapy / adverse effects
  • Humans
  • Male
  • Risk Factors

Substances

  • Estrogens
  • Estradiol

Grants and funding

This work was supported by Alzheimer’s New Zealand (AK; 3718869), Freemasons New Zealand (AK; 3719321 and 501029), Alzheimer’s New Zealand Charitable Trust (AK; 3720863), Health Research Council of New Zealand (RF; 3627373).